Associations and gastrointestinal symptoms in women with endometriosis in comparison to women with irritable bowel syndrome: a study based on a population cohort

Table 4 Gastrointestinal symptoms of the study population

	Endometriosis		P- value	IBS		P-value	Endometriosis + IBS		P-value	Healthy participants*		P-value*
	Median (IQR)	No		Median (IQR)	No		Median (IQR)	No		Median (IQR)	No
Pain 5 (1–15)	26 (4–56)	8	0.628	50 (22–67)	280	< 0.001	58 (25–70)	11	0.004	20 (4–48)	193	< 0.001
Diarrhea 3 (0–10)	19 (4–44)	7	0.480	40 (10–67)	272	< 0.001	44 (6–56)	10	0.147	10 (1–48)	193	< 0.001
Constipation 9 (1–22)	29 (1–50)	7	0.471	47 (5–69)	264	< 0.001	45 (21–51)	11	0.018	9 (0–47)	193	< 0.001
Bloating/flatulence 13 (1–29)	40 (3–84)	9	0.475	66 (48–79)	283	< 0.001	67 (25–74)	13	0.026	31 (10–60)	197	< 0.001
Vomiting/nausea 2 (0–3)	1 (0.-29)	7	0.366	18 (0–54)	258	0.016	18 (3–61)	11	0.167	4 (0–48)	189	0.051
Symptoms´ influence on daily life 4 (0–16)	50 (7–76)	9	0.185	58 (24–75)	287	< 0.001	50 (25–65)	13	0.008	21 (5–50)	202	< 0.001
Psychological well-being 2 (0–18)	20 (6–46)	36	0.579	30 (14–58)	388	< 0.001	49 (23–60)	19	0.002	20 (7–35)	1331	< 0.001

Symptoms in the past 2 weeks were measured by the visual analog scale for irritable bowel syndrome (VAS-IBS) where 0 mm means no symptoms and 100 mm means maximal symptoms [26]. Reference values for healthy women are given within brackets [27]. Values are presented as the median and interquartile range (IQR). Mann-Whitney U test was used for comparison with healthy participants and Kruskal-Wallis test* at group level. P-value < 0.05 was considered statistically significant
* Participants without endometriosis and/or IBS

ISSN: 1471-230X